Friday 16 October 2026
Export ZNTL’s income statement to Excel — free account
Zentalis Pharmaceuticals, Inc.
ZNTL Healthcare Biotechnology
Zentalis Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $67.4 million. In the quarter to June 2026, EPS fell 59.5% and free cash flow fell 9.06%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.13
0.11
−4.91%
Follow ZNTL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
4.64 | 6.01 | 6.73 | 7.55 | |
Current Ratio |
4.82 | 6.19 | 6.93 | 7.76 | |
Net Debt/EBITDA |
3.94 | 5.58 | 6.53 | 8.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.93 | 0.88 | 1.01 | |
Capex/Depreciation |
0.00 | 0.47 | (0.47) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.52) | (0.47) | (0.43) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.52) | (0.47) | (0.43) | (0.37) | |
Cash per Share |
2.45 | 3.01 | 3.42 | 3.89 | |
Shareholders Equity per Share |
2.01 | 2.60 | 3.01 | 3.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.01 | 2.60 | 3.01 | 3.51 | |
Free Cash Flow |
(37.24) | (32.99) | (30.81) | (26.96) | |
Working Capital |
143.65 | 182.86 | 216.63 | 251.13 | |
Capital Expenditures |
0.00 | (0.03) | 0.13 | 0.00 | |
Net Current Asset Value |
109.60 | 147.71 | 180.43 | 213.93 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
5.93 | 7.57 | 7.32 | 7.62 | |
Average Assets |
283.52 | 318.54 | 359.65 | 388.96 | |
Average Common Equity |
209.07 | 239.03 | 276.70 | 303.60 |
Columns are period end dates